People

Stuart M. Falber

Partner

Co-Chair, Life Sciences Group

Falber, Stuart M.

Stuart Falber represents clients in the life sciences area. For more than 20 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks and venture capital funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Recent Highlights

Representative transactions in which Mr. Falber has served as counsel include:

Venture Capital Transactions

  • Aileron Therapeutics, Inc. in its $48 million Series E financing rounds
  • Apellis Pharmaceuticals, Inc. in its $47 million Series D financing round
  • Celtaxsys, Inc. in its $40 million Series D financing round
  • Tokai Pharmaceuticals, Inc. in its 35.5 million Series E financing round
  • Trevi Therapeutics, Inc. in its $26 million Series B financing round

Public Offerings

  • Argos Therapeutics, Inc. in its $49.6 million initial public offering
  • Epizyme in multiple follow-on public offerings, including its $137.7 million public offering in January 2016
  • Idera Pharmaceuticals, Inc. in multiple follow-on public offerings, including its $86.25 million public offering in January 2015
  • The Medicines Company in a follow-on public offering raising a total of $201.2 million
  • Tetraphase Pharmaceuticals, Inc. in its $80.5 million initial public offering and in multiple follow-on public offerings, including its $173.1 million public offering in March 2015
  • Tokai Pharmaceuticals in its $105.3 million initial public offering

Merger and Acquisition Transactions

  • The Medicines Company in its acquisition of Incline Therapeutics for up to $390 million, including contingent payments
  • Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for $144 million
  • Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to $640 million, including contingent payments
  • Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for $16 billion

PIPE and 144A Transactions

  • The Medicines Company in 144A convertible note offerings, including its $350 million offering in January 2015
  • Argos Therapeutics, Inc. in its $60 million PIPE transaction
  • Idera Pharmaceuticals, Inc. in PIPE transactions raising a total of $17 million
  • New Leaf Ventures  in a PIPE transaction by MEI Pharma, Inc. raising a total of $27.5 million

Corporate Collaborations and Licensing Transactions

  • ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

 

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association, as well as the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Honors & Awards

Publications & News

View

November 14, 2017

WilmerHale Reps Apellis Pharmaceuticals in Initial Public Offering

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced the closing of its initial public offering.

October 26, 2017

WilmerHale Serves as Counsel to Idera Pharmaceuticals in Public Offering of Common Stock

Idera Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $1.50 per share.

October 5, 2017

WilmerHale Reps Disarm Therapeutics in $30M Series A Financing

Disarm Therapeutics, a new biotechnology company developing therapeutics to treat patients with neurological diseases by preventing axonal degeneration, announced the recent completion of a $30 million Series A financing.

September 29, 2017

Epizyme Announces Closing of Public Offering of Common Stock

Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced the closing of its public offering of 10,557,000 shares of its common stock.

August 30, 2017

WilmerHale Reps Apellis Pharmaceuticals in $60 Million Series E Financing

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, announced the closing of a $60 million Series E preferred stock financing.

August 16, 2017

WilmerHale Lawyers Named Among the 2018 Best Lawyers in America®, Nine Recognized as Lawyers of the Year

Best Lawyers in America®—the oldest and most respected peer-review publication in the legal industry—recognizes 107 WilmerHale lawyers and names nine partners as Lawyers of the Year in its 24th edition.

August 14, 2017

WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

August 7, 2017

WilmerHale Reps Tetraphase Pharmaceuticals in $65M Public Offering of Common Stock

Tetraphase Pharmaceuticals, Inc. has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.

July 24, 2017

WilmerHale Represents Trevi Therapeutics in Securing $50M in Series C Financing

The WilmerHale deal team counseling Trevi Therapeutics was led by Stuart Falber and included Sam Rothberg and Cara Fonseca.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

Practices

Skip Navigation Links.

Education

JD, magna cum laude, University of Pennsylvania Law School, Order of the Coif; Senior Editor, University of Pennsylvania Law Review

BA, cum laude, Tufts University

Bar Admissions

Massachusetts

Skip Navigation Links.